Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global markets.Keytruda (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of cancer.Under the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on Thursday.Subject to certain exceptions, each party will have the right to commercialise the product globally.Unlike traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical conditions.In India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck cancers.Keytruda helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli said.Keytruda has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
28 minutes ago
- Time of India
Court orders hair transplant clinic to pay Rs 6.3 lakh after complainant sees no improvement
The New Delhi District Consumer Disputes Redressal Commission has directed DHI Asian Roots, a private clinic, to refund Rs 5,01,000 and pay additional compensation after finding it guilty of performing a hair transplant procedure without a valid licence or government approval. The order was issued on May 22, 2025, following a complaint filed by a patient who alleged lack of results and unqualified medical staff, a TOI report stated. Commission highlights lack of licence and medical standards The commission observed that the clinic, a unit of SPA Yoga Private Limited, did not produce any government authorisation to perform modern scientific hair implantation procedures. It also failed to show approval for employing qualified doctors. The bench, led by president Poonam Chaudhry and members Bariq Ahmad and Shekhar Chandra, stated that conducting such medical procedures without proper licensing and expertise amounts to unfair trade practice. The bench said, 'It is essential that medical procedures are conducted only by qualified professionals holding valid licences, and in properly registered clinics that comply with established medical standards.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 Most Beautiful Female Athletes in the World Click Here Undo Refund, compensation, and cost awarded to complainant The commission ordered the clinic to refund Rs 5,01,000 to the complainant. Additionally, it directed payment of Rs 1,00,000 as compensation for mental harassment and Rs 30,000 towards litigation costs. The complainant had undergone three sessions at the clinic but reported no visible improvement in hair condition. The commission noted, 'Despite the complainant undergoing three sessions, there was not even 1% improvement. The clinic failed to provide any explanation for the lack of results.' Live Events Complainant raised issue of unfair trade and unqualified staff According to the complainant, the clinic assured hair regrowth or replacement under the supervision of expert doctors as mentioned in its brochure. He alleged that the clinic employed unqualified staff and carried out procedures without proper medical licences. Despite paying the full amount in 2013, he did not see any results, which led him to file a complaint. Clinic claimed procedures were informed and professional The clinic defended itself by stating that the complainant was made aware of the pros and cons of the transplant procedure. It argued that results varied by individual, and that the procedures were conducted in a professional manner, including additional work at the complainant's request. The clinic maintained that the patient's dissatisfaction stemmed from impatience and not following medical advice.
Time of India
29 minutes ago
- Time of India
Qualcomm Snapdragon Auto Day India: Check out the date, location, themes and why it matters for automakers
Snapdragon Auto Day India drives innovation forward as Qualcomm gears up for its inaugural automotive showcase in New Delhi. This high‑profile event, held in partnership with Amazon Web Services, spotlights Qualcomm's cutting‑edge role in shaping connected vehicles, software‑defined mobility, and advanced driver assistance systems (ADAS). Industry leaders from OEMs, Tier 1 suppliers, and the broader ecosystem will gather to explore how Snapdragon Auto platforms and Vehicle‑to‑Everything (V2X) technology are set to transform mobility in India and beyond. With a strong emphasis on AI‑powered in‑car experiences, cloud integration, and intelligent mobility, this event marks a pivotal moment in India's rise as an automotive innovation hub. Stay tuned for insights on how Qualcomm's Auto Day plans to redefine future driving experiences. When is Snapdragon Auto Day India? In collaboration with AWS (Amazon Web Services), Qualcomm announced today that the inaugural "Snapdragon Auto Day" will occur in New Delhi on July 30, 2025. Making Indian roads safer and smarter while exhibiting the technology, cross-border learning, and partnerships that will shape the next ten years of mobility is the audacious goal of this historic occasion. Aim of Snapdragon Auto Day Qualcomm today announced its first-ever 'Snapdragon Auto Day' | Credit: Qualcomm Snapdragon Auto Day aims to introduce Qualcomm's hardware and software-level smart vehicle solutions to leaders in the automotive industry, automakers, Tier 1 stakeholders, and linked ecosystem partners. Qualcomm is currently at the forefront of software-based smart mobility solutions worldwide. It provides several smart connectivity and smart-car capabilities, including Cockpit, Ride, Car-to-Cloud, and Snapdragon's Auto Connectivity. Furthermore, Indian automakers would be able to use and incorporate all of these clever Qualcomm advancements into their upcoming models. Qualcomm Car-to-Cloud, for instance, will enable OEMs to provide "seamless in-vehicle connectivity and robust cloud integration." With a contemporary 3D UI/UX design language, brands may include Snapdragon's Cockpit experience to provide AI-based context-aware automotive solutions. Additionally, Qualcomm OEM partnerships will be able to provide intelligent Advanced Driver Assistance Systems (ADAS) for intelligent road safety features thanks to Snapdragon Auto Connectivity and Snapdragon Ride. Furthermore, when paired with its Vehicle-to-Everything (V2X) technology, Indian automakers may facilitate increased situational awareness and real-time driving communication. Qualcomm wants to use smarter mobility solutions to draw attention to the need for safer roads in India with Snapdragon Auto Day.
New Indian Express
32 minutes ago
- New Indian Express
Medi Assist Healthcare buys Paramount TPA for Rs 312 crore
MUMBAI: The Bengaluru-based third-party insurance service provider Medi Assist Healthcare Services has acquired 100% stake in the rival firm Paramount Health Services & Insurance TPA for a total consideration of around Rs 312 crore. This acquisition marks pivotal step in Medi Assist's continued growth strategy, reinforcing its position as the country's largest health benefits administrator. The transaction adds Rs 4,000 crore of health premia under administration to the only publicly traded company in this segment in India, Medi Assist said in a statement on Wednesday.
